The Proliferative Diabetic Retinopathy (PDR) drugs in development market research report provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Proliferative Diabetic Retinopathy (PDR). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Proliferative Diabetic Retinopathy (PDR) by seven companies/universities/institutes. The top development phase for Proliferative Diabetic Retinopathy (PDR) is phase ii with four drugs in that stage. The Proliferative Diabetic Retinopathy (PDR) pipeline has six drugs in development by companies and one by universities/ institutes. Some of the companies in the Proliferative Diabetic Retinopathy (PDR) pipeline products market are: Boehringer Ingelheim International, Kubota Vision and Novartis.
The key targets in the Proliferative Diabetic Retinopathy (PDR) pipeline products market include DNA (Apurinic or Apyrimidinic Site) Endonuclease, Vascular Endothelial Growth Factor A, and Semaphorin 3A.
The key mechanisms of action in the Proliferative Diabetic Retinopathy (PDR) pipeline product include Vascular Endothelial Growth Factor A Inhibitor with one drug in Phase III. The Proliferative Diabetic Retinopathy (PDR) pipeline products include four routes of administration with the top ROA being Oral and three key molecule types in the Proliferative Diabetic Retinopathy (PDR) pipeline products market including Small Molecule, and Monoclonal Antibody.
Proliferative Diabetic Retinopathy (PDR) overview
Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. PDR occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue, causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision, and difficulty with color perception.
For a complete picture of Proliferative Diabetic Retinopathy (PDR)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
